Source: Eur Respir J 2014; 43: 409-420
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Lea Simon, Plumb Jonathan, Metcalfe Hannah, Spicer Dianne, Woodman Paul, Fox J. Craig, Singh Dave. The effect of peroxisome proliferator-activated receptor-? ligands on in vitro and in vivo models of COPD. Eur Respir J 2014; 43: 409-420

Member's Comments

No comment yet.

Related content which might interest you: The interaction of glucocorticoid and peroxisome proliferator-activated receptor γ agonist in asthmatic mice Source: Eur Respir J 2006; 28: Suppl. 50, 226s Year: 2006 Relationship between peroxisome proliferator-activated receptor α and neutrophils in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 452s Year: 2004 Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD Source: Eur Respir J 2007; 30: 245-252 Year: 2007 Role of exogenous ligands for the peroxisome proliferator-activated receptor-β/δ in the development of bleomycin-induced lung injury Source: Annual Congress 2010 - Cell biology and immunology of lung disease Year: 2010 Activation of airway epithelial cell inhibited by peroxisome proliferator-activated receptor γ Source: Eur Respir J 2006; 28: Suppl. 50, 229s Year: 2006 Impacts of peroxisome proliferator-activated receptor gamma activation on cigarette smoke-induced exacerbated response to bacteria Source: Eur Respir J 2015; 45: 191-200 Year: 2015 The effects of exercise training on peroxisome proliferator-activated receptor (PPAR) expression in skeletal muscle in COPD Source: Annual Congress 2009 - Emerging physiology behind pulmonary rehabilitation Year: 2009 The role of peroxisome proliferator-activated receptor γ in pulmonary hypertension Source: Annual Congress 2009 - Pulmonary circulation II Year: 2009 Role of peroxisome proliferator activated receptor γ in COPD Source: Annual Congress 2009 - Airway inflammation and host defence Year: 2009 PPAR-γ agonists as therapy for diseases involving airway neutrophilia Source: Eur Respir J 2004; 24: 18-23 Year: 2004 The relationship of peroxisome proliferator activated receptor γ ligands and IL-6 in sepsis of rats Source: Annual Congress 2009 - Acute lung injury and biomarkers Year: 2009 Peroxisome proliferator-activated receptors: a therapeutic target in COPD? Source: Eur Respir J 2008; 31: 502-508 Year: 2008 Diminished peroxisome proliferator-activated receptor (PPAR) regulation as a potential mechanism for the persistent inflammation in chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 856s Year: 2006 Diminished peroxisome proliferator-activated receptor (PPAR) regulation as a potential mechanism for the persistent inflammation in chronic obstructive pulmonary disease Source: Eur Respir Rev 2006; 15: 211-212 Year: 2006 Role of NF-?B and PPAR-? in lung inflammation induced by monocyte-derived microparticles Source: Eur Respir J 2011; 37: 1494-1502 Year: 2011 Peroxisome proliferator activated receptor gamma (PPARγ) agonist rosiglitizone inhibits upregulation of mucin gene expression in two airway epithelial cell lines Source: Eur Respir J 2005; 26: Suppl. 49, 97s Year: 2005 Peroxisome proliferator-activated receptor gamma antagonist, GW9662, inhibits microparticles generation by calcium ionophore-stimulated monocytes/macrophages Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008 The inhibitory effect of peroxisome proliferator-activated receptor-γ ligands on malignant pleural mesothelioma cell growth Source: Annual Congress 2008 - Biology and diagnosis of thoracic tumours Year: 2008 Peroxisome proliferator-activated receptor γ inhibits acrolein-induced airway mucus hypersecretion in rats Source: Annual Congress 2008 - Inflammatory trigger mechanisms in asthma and COPD Year: 2008 Effects of peroxisome proliferators-activated receptor-α, γ agonists on acute lung injury rats induced by lipopolysaccharide Source: Eur Respir J 2006; 28: Suppl. 50, 397s Year: 2006